Related Experiment Video

Updated: May 3, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

8.9K

Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption

Chan Kim1, Hanseul Yang1, Yoko Fukushima2

  • 1National Research Laboratory of Vascular Biology and Stem Cells, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 305-701, Korea; Graduate School of Medical Science and Engineering, KAIST, Daejeon 305-701, Korea.

Cancer Cell
|January 18, 2014
PubMed

Insights

Blocking RhoJ, a protein in endothelial cells, inhibits tumor blood vessel growth and disrupts existing ones. This dual action offers a potent anticancer strategy with fewer side effects than current therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Vascular Biology

Background:

  • Current antiangiogenic therapies are cytostatic and cause systemic side effects.
  • Tumor progression relies on angiogenesis and vascular integrity.
  • Targeting endothelial cell signaling pathways offers a novel therapeutic approach.

Purpose of the Study:

  • To investigate the role of RhoJ, an endothelial-enriched Rho GTPase, in tumor progression.
  • To evaluate RhoJ blockade as a therapeutic strategy against tumor vasculature.
  • To assess the combination effects of RhoJ blockade with other anticancer agents.

Main Methods:

  • Utilized RhoJ blockade in preclinical tumor models.
  • Investigated the activation of the RhoA-ROCK signaling pathway in tumor endothelial cells.
  • Assessed the impact on tumor angiogenesis and vascular integrity.
  • Evaluated combination therapy with cytotoxic, antiangiogenic, and vascular-disrupting agents.

Main Results:

  • RhoJ blockade inhibits tumor angiogenesis.
  • RhoJ blockade disrupts preformed tumor vessels via RhoA-ROCK pathway activation.
  • Combined RhoJ blockade with other agents enhanced anticancer effects.
  • RhoJ blockade demonstrated selectivity and minimal side effects.

Conclusions:

  • RhoJ blockade is a promising therapeutic strategy targeting tumor vasculature.
  • Targeting RhoJ offers a dual mechanism of action: inhibiting angiogenesis and disrupting existing tumor vessels.
  • Combination therapy with RhoJ blockade potentiates anticancer efficacy.

More Related Videos

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis06:12

HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis

Published on: June 24, 2019

16.9K
A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

14.8K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K